Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Correction to
*Lancet Oncol* 2021; 22: 309–20

Spencer K, Jones CM, Girdler R, et al. The impact of the COVID-19 pandemic on radiotherapy services in England, UK: a population-based study. *Lancet Oncol* 2021; 22: 309–20—In Figure 2 of this Article, the second and subsequent graphs in the lung and bladder cancer panels have been corrected so that total treatments sum to 100%. These corrections have been made to the online version as of June 1, 2021.

Correction to
*Lancet Oncol* 2021; 22: 581–83

Waissengrin B, Agbarya A, Safadi E, Padova H, Wolf J. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. *Lancet Oncol* 2021; 22: 581–83—In the fourth paragraph of this Comment, the IQR for the median number of days after the second vaccine dose should have been “(IQR 12–31)”, and the seventh paragraph should have read “Most patients (97 [72%] of 134) were treated with immune checkpoint inhibitors alone and 37 (28%) were treated with a combination of immune checkpoint inhibitors and chemotherapy. A similar rate of side-effects was observed in both treatment groups (31 [32%] of 97 vs 16 [43%] of 37; χ² p=0.22)”. And in paragraph ten, the number of patients who previously had grade 2 or worse immune checkpoint inhibitor-related side-effects should have been 47 (35%) of 134, and the third sentence should have read “There was no significant difference in the number of patients who reported systemic side-effects after the second dose of vaccine between those who had reported previous immune-related side-effects and those who had not (16 [34%] of 47 vs 30 [34%] of 87; p=0.96)”. These corrections have been made to the online version as of April 30, 2021.

Correction to
*Lancet Oncol* 2021; 22: 678–89

Matasar MJ, Capra M, Özcan M, et al. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Oncol* 2021; 22: 678–89—In this article, in figure 2, parts A, B, and C, the first timepoint on the x-axes should be 6 months; in addition, the appendix has been corrected. These corrections have been made to the online version as of June 1, 2021.

Correction to
*Lancet Oncol* 2021; 22: 872–82

Yu EY, Petrylak DP, O’Donnell PH, et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. *Lancet Oncol* 2021; 22: 872–82—In figure 2B of this Article, the symbols for complete response and partial response were switched. The written interpretation remains the same. This correction has been made to the online version as of June 1, 2021, and the printed version is correct.

Published Online
April 30, 2021
https://doi.org/10.1016/S1470-2045(21)00264-3